Skip to content

Adrenalectomy for Solitary Adrenal Gland Metastases

The Use of Adrenalectomy in Patients With Solitary Adrenal Gland Metastases

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01135238
Enrollment
168
Registered
2010-06-02
Start date
2009-11-30
Completion date
2010-11-30
Last updated
2011-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adrenalectomy, Adrenal Gland Metastases

Keywords

adrenalectomy, metastasis, morbidity, mortality, survival

Brief summary

The adrenal glands are one of the most common organs involved in metastatic disease. Metastases are the second most common type of adrenal mass, second only to adenomas. It is a frequent finding during autopsy with a reported rate as high as 27% in patients with known primary malignancy. Although several studies have found an increased survival in patients who undergo resection of solitary adrenal metastases the indications for adrenalectomy in cases of metastatic adrenal tumor remain controversial. Collinson et al reported an increased survival in patients with melanoma. Median survival was 16 months for patients who underwent adrenalectomy compared to 5 months for patients with documented adrenal metastases treated non surgically. The aim of this study is to compare retrospectively in case and control study, performing adrenalectomy, open or laparoscopic, versus supportive treatment for patients with solitary adrenal gland metastases. The investigators will review charts of patients between January 1994 and November 2009 who had adrenal gland metastases. The variables the inevstigators will compare are mortality, morbidity, primary tumour sites, histological cell type, age, tumour size, presence of synchronous metastases, mean time from diagnosis of primary tumor to treatment of adrenal metastases, indication for adrenalectomy, partial versus total adrenalectomy, suspected versus confirmed metastatic disease.

Interventions

None listed

Sponsors

Mayo Clinic
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Metastatic disease to the adrenal gland

Exclusion criteria

* Primary adrenal neoplasm

Design outcomes

Primary

MeasureTime frameDescription
Adrenalectomy improves overall survival in patients with solitary metastasis25 yearsSurvival data compared to historic controls

Secondary

MeasureTime frameDescription
Adrenalectomy can be performed with minimal morbidity in patients with metastatic lesions to the adrenal gland.25 yearsOperative outcomes compared to historic control patients undergoing adrenalectomy for non-maligant disorders.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026